The highest prevalence of MDS is in patients over 60 years of age. According to the American Cancer Society and the Aplastic Anemia and MDS International Foundation, there are approximately 10,000 - 30,000 new cases of MDS in the United States each year. Survival ranges from six months to many years for the different subtypes of MDS.
DNA methylation and histone deacetylation are two of the more studied
epigenetic regulators of gene expression. Epigenetics refers to changes in
the regulation of gene expression. Epigenetic changes can silence gene
expression and, unlike DNA mutations, may be reversed by targeting the
enzymes involved. The silencing of key cell cycle control genes and tumor
suppressor genes through these two mechanisms of epigenetic regulation have
been demonstrated in vitro and in vivo in hematological malignancies and in
solid tumors. Vidaza has been shown to reverse the effects of DNA
hypermethylation with subsequent gene re-expression and likewise MGCD0103
has been shown, in vivo, to reverse the effects of inappropriate
deacetylation resulting in gene expression reactivation. The epigenetic
approach to cancer therapy is that rather than usin
|SOURCE Pharmion Corporation|
Copyright©2007 PR Newswire.
All rights reserved